The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
about
Applying a Weight-of-Evidence Approach to Evaluate Relevance of Molecular Landscapes in the Exposure-Disease ParadigmAberrant splicing and drug resistance in AMLBlood disorders typically associated with renal transplantationAberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukemia.Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes.Early B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia.The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapyMethylxanthines Increase Expression of the Splicing Factor SRSF2 by Regulating Multiple Post-transcriptional MechanismsGenomic dynamics associated with malignant transformation in IDH1 mutated gliomas.Clonogenic multiple myeloma cells have shared stemness signature associated with patient survivalClinical and biological implications of driver mutations in myelodysplastic syndromes.ASXL1 mutations in myeloid neoplasms: pathogenetic considerations, impact on clinical outcomes and survival.Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified.Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome.Does aberrant membrane transport contribute to poor outcome in adult acute myeloid leukemia?Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia.CHFR hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome.Acute myeloid leukemia with inv(16)(p13.1q22), abnormal eosinophils, and absence of peripheral blood and bone marrow blasts.Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine.Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile.
P2860
Q26784509-9354C516-C88B-4161-9D28-41CB9C38E389Q28076011-9FAD8A08-0353-4E38-A355-59023250F29BQ33421793-951C1A63-1989-4EA7-9C8D-A477F07BF600Q34047994-93A50C9F-9BD4-4E56-BC2C-3E87EFD88E68Q34457432-C691D801-55C7-4860-969D-EACE2DBBC5CBQ35030109-D2BC9018-88DC-44C6-8B43-F024936D888DQ35254822-B184E288-1FA6-4F16-ACDA-3783E06B3B60Q35721733-DAAAAD7E-FA2E-49C6-AECC-0D03136B2E96Q36685471-C465B187-2060-4D49-84A6-178ACF1CFEAEQ37207661-BDCF8F7A-5B1E-4862-A9E8-87827E5BE83DQ37334716-EE45F9F8-C774-46FB-B45B-5F2A51C40D65Q38777486-86008026-A59A-4ABC-A365-A1320F8E4C34Q39770083-F448C359-1C63-445E-8FEE-7BA0460EEC70Q41191920-4EF01588-64BE-45AF-9BF2-C5CF4DBC966DQ41493120-6A70D683-54FA-4CF4-86FF-47B451B32330Q47136441-7295BB77-D819-4954-9F30-12F2EB854A6AQ52904336-5F3E3143-DFAB-4426-89E9-8EC947E3CC00Q53224430-97BCC46C-6D7A-454B-ABEA-C1ACE3E2E44BQ53820609-385EC846-CA46-4209-AB7D-B310DEFD4947Q55379234-748EDA4D-7082-47F3-A39F-469DD753DF4D
P2860
The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
@ast
The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
@en
The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
@nl
type
label
The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
@ast
The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
@en
The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
@nl
prefLabel
The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
@ast
The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
@en
The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
@nl
P2860
P1476
The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome
@en
P2093
Alfonso Quintás-Cardama
Gilbert Cote
P2860
P304
P356
10.1158/1541-7786.MCR-12-0695
P577
2013-05-03T00:00:00Z